Search results for " Mantle"
showing 5 items of 75 documents
Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma
2001
Abstract Patients with mantle cell lymphoma (MCL) may present with either nodal or leukemic disease. The molecular determinants underlying this different biologic behavior are not known. This study compared the pattern of genetic abnormalities in patients with nodal and leukemic phases of MCL using comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) for specific gene loci. Although both leukemic and nodal MCL showed similar genomic patterns of losses (involving 6q, 11q22-q23, 13q14, and 17p13) and gains (affecting 3q and 8q), genomic loss of chromosome 8p occurred more frequently in patients with leukemic disease (79% versus 11%,P < .001). Subsequent…
Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma (Rel/Refr Mcl) in Routin…
2014
ABSTRACT Aim: Temsirolimus (TEMS), an mTOR-inhibitor, is approved in the EU for the treatment of patients (pts) with relapsed or refractory (rel/refr) MCL. A pivotal study demonstrated significantly longer progression free survival with TEMS (175 mg weekly for 3 weeks followed by 75 mg weekly) in rel/refr MCL pts compared to investigatoŕs choice therapy (4.8 mo vs 1.9 mo; P = .0009). To evaluate safety and efficacy of TEMS in an unselected patient population during clinical routine, a prospective non-interventional study with TEMS in rel/refr MCL pts is useful. Here we report on interim results of the study. Methods: A German multicenter registry for rel/refr MCL pts treated with TEMS was s…
Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma (REL/REFR MCL) in the Us…
2012
ABSTRACT Background Temsirolimus (TEMS), an mTOR-inhibitor, is approved the EU for the treatment of patients (pts) with relapsed or refractory MCL (rel/refr). A pivotal study demonstrated significantly longer progression free survival with TEMS (175mg weekly for 3 weeks followed by 75mg weekly) in rel/refr MCL pts compared to investigatoŕs choice therapy (4.8 mo vs 1.9 mo; P = .0009). To better identify safety and efficacy of TEMS in an unselected patient population during clinical routine a prospective non-interventional study with TEMS in rel/refr MCL-pts was started. Here we report on interim results of the study. Methods A registry for rel/refr MCL pts treated with TEMS was started in G…
Experimental Constraints on the Deep Magma Feeding System at StromboliVolcano, Italy
2009
International audience; New experiments have been performed on a high-K basalt (PST-9) from Stromboli volcano, Italy, to constrain the physical conditions of golden pumice magmas at their storage level and discuss their petrogenesis. Fluid-present, H2O- and CO2-bearing, near-liquidus experiments were performed at 11508C between 100 and 400MPa and under oxidizing conditions. Glasses were analyzed by Fourier transform IR spectroscopy and their H2O and CO2 concentrations compared with those in glass inclusions.Most glass inclusions cluster near the 200MPa isobar, suggesting entrapment at a depth of ~8 km. Golden pumice magmas have viscosities of 7.9 Pa s and densities of 2.48-2.57 g/cm3. Compo…
First volatile inventory for Gorely volcano, Kamchatka
2012
We report here the very first assessment of volatile flux emissions from Gorely, an actively degassing volcano in Kamchatka. Using a variety of in situ and remote sensing techniques, we determined the bulk plume concentrations of major volatiles (H2O 93.5%, CO2, 2.6%, SO2 2.2%, HCl 1.1%, HF 0.3%, H2 0.2%) and trace-halogens (Br, I), therefore estimating a total gas release of 11,000 tons·day−1 during September 2011, at which time the target was non-eruptively degassing at 900°C. Gorely is a typical arc emitter, contributing 0.3% and 1.6% of the total global fluxes from arc volcanism for CO2 and HCl, respectively. We show that Gorely's volcanic gas (H2O/SO2 43, CO2/SO2 1.2, HCl/SO2 0.5) is a…